Click image to enlarge
Category: Rapid Molecular Testing (Click here to return)
CPO Detection Assay
BD
Click here to view supplier website

BD announces FDA approval for its Check-Points CPO assay for the BD MAX fully automated molecular platform. Created to help manage antibiotic-resistant hospital-acquired infections (HAIs), BD’s molecular panel can detect 5 of the most common carbapenemase genes in 2.5 hours. This detection assay is an addition to BD’s portfolio dedicated to reducing transmission and outbreak of deadly pathogens, allowing hospitals and clinical laboratories to offer efficient time to result, and enabling immediate deployment of control measures and treatment.


BD

Click here to request more information
Entry published in MLM March 2020